ARPC5L
gene geneOn this page
Also known as MGC3038ARC16-2
Summary
ARPC5L (actin related protein 2/3 complex subunit 5 like, HGNC:23366) is a protein-coding gene on chromosome 9q33.3, encoding Actin-related protein 2/3 complex subunit 5-like protein (Q9BPX5). May function as component of the Arp2/3 complex which is involved in regulation of actin polymerization and together with an activating nucleation-promoting factor (NPF) mediates the formation of branched actin networks.
Predicted to enable actin filament binding activity. Predicted to be involved in Arp2/3 complex-mediated actin nucleation and cell migration. Located in extracellular exosome and focal adhesion.
Source: NCBI Gene 81873 — RefSeq curated summary.
At a glance
- Clinical variants (ClinVar): 23 total
- Druggable target: yes
- MANE Select transcript:
NM_030978
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:23366 |
| Approved symbol | ARPC5L |
| Name | actin related protein 2/3 complex subunit 5 like |
| Location | 9q33.3 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | MGC3038, ARC16-2 |
| Ensembl gene | ENSG00000136950 |
| Ensembl biotype | protein_coding |
| Entrez | 81873 |
Gene structure
Transcript identifiers
Ensembl transcripts: 6 — 5 protein_coding, 1 protein_coding_CDS_not_defined
ENST00000259477, ENST00000353214, ENST00000465124, ENST00000866775, ENST00000911390, ENST00000964188
RefSeq mRNA: 1 — MANE Select: NM_030978
NM_030978
CCDS: CCDS6859
Canonical transcript exons
ENST00000353214 — 6 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000806655 | 124873692 | 124873764 |
| ENSE00001379505 | 124868428 | 124869439 |
| ENSE00001397399 | 124876878 | 124877733 |
| ENSE00001404537 | 124862130 | 124862398 |
| ENSE00001432409 | 124863988 | 124864107 |
| ENSE00003693470 | 124874975 | 124875151 |
Expression profiles
Bgee: expression breadth ubiquitous, 292 present calls, max score 99.35.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 46.6947 / max 431.3695, expressed in 1827 samples.
FANTOM5 promoters (4 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 98491 | 44.6854 | 1826 |
| 98489 | 1.9801 | 921 |
| 98492 | 0.0214 | 7 |
| 98490 | 0.0078 | 3 |
Top tissues by expression
292 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| secondary oocyte | CL:0000655 | 99.35 | gold quality |
| middle temporal gyrus | UBERON:0002771 | 98.22 | gold quality |
| adult organism | UBERON:0007023 | 97.33 | gold quality |
| gingival epithelium | UBERON:0001949 | 97.25 | gold quality |
| esophagus squamous epithelium | UBERON:0006920 | 97.18 | gold quality |
| right testis | UBERON:0004534 | 97.07 | gold quality |
| gingiva | UBERON:0001828 | 97.04 | gold quality |
| endothelial cell | CL:0000115 | 97.03 | gold quality |
| left testis | UBERON:0004533 | 97.03 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 97.01 | gold quality |
| Brodmann (1909) area 23 | UBERON:0013554 | 97.00 | gold quality |
| epithelium of esophagus | UBERON:0001976 | 96.94 | gold quality |
| squamous epithelium | UBERON:0006914 | 96.77 | gold quality |
| pharyngeal mucosa | UBERON:0000355 | 96.75 | gold quality |
| dorsolateral prefrontal cortex | UBERON:0009834 | 96.62 | gold quality |
| right frontal lobe | UBERON:0002810 | 96.56 | gold quality |
| oocyte | CL:0000023 | 96.49 | gold quality |
| esophagus mucosa | UBERON:0002469 | 96.45 | gold quality |
| tendon of biceps brachii | UBERON:0008188 | 96.38 | gold quality |
| cingulate cortex | UBERON:0003027 | 96.37 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 96.37 | gold quality |
| mammalian vulva | UBERON:0000997 | 96.25 | gold quality |
| frontal cortex | UBERON:0001870 | 96.25 | gold quality |
| frontal lobe | UBERON:0016525 | 96.25 | gold quality |
| prefrontal cortex | UBERON:0000451 | 96.23 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 96.23 | gold quality |
| Brodmann (1909) area 46 | UBERON:0006483 | 96.21 | gold quality |
| primary visual cortex | UBERON:0002436 | 96.10 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 96.08 | gold quality |
| pons | UBERON:0000988 | 96.05 | gold quality |
Single-cell (SCXA)
Detected in 6 experiment(s), a significant marker in 5.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-MTAB-9467 | yes | 33.64 |
| E-MTAB-10287 | yes | 28.29 |
| E-MTAB-10042 | yes | 12.00 |
| E-MTAB-10553 | yes | 7.44 |
| E-MTAB-6379 | no | 1051.91 |
| E-ANND-3 | no | 0.00 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
51 targeting ARPC5L, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-126-5P | 100.00 | 72.71 | 3180 |
| HSA-MIR-548AN | 99.97 | 70.91 | 2817 |
| HSA-MIR-96-5P | 99.95 | 72.80 | 2140 |
| HSA-MIR-545-3P | 99.95 | 70.74 | 2783 |
| HSA-MIR-3910 | 99.95 | 71.13 | 2227 |
| HSA-MIR-12133 | 99.92 | 71.82 | 2006 |
| HSA-MIR-1271-5P | 99.91 | 71.99 | 1972 |
| HSA-MIR-329-3P | 99.91 | 66.56 | 1234 |
| HSA-MIR-362-3P | 99.91 | 66.38 | 1267 |
| HSA-MIR-10523-5P | 99.91 | 69.22 | 2038 |
| HSA-MIR-95-5P | 99.89 | 72.17 | 3973 |
| HSA-MIR-4697-3P | 99.89 | 67.09 | 1123 |
| HSA-MIR-4496 | 99.88 | 68.89 | 2236 |
| HSA-MIR-4698 | 99.84 | 71.41 | 4303 |
| HSA-MIR-4659A-3P | 99.80 | 72.62 | 4248 |
| HSA-MIR-4659B-3P | 99.80 | 72.62 | 4248 |
| HSA-MIR-6887-3P | 99.66 | 67.83 | 1778 |
| HSA-MIR-4690-5P | 99.65 | 66.24 | 813 |
| HSA-MIR-651-5P | 99.64 | 68.49 | 1104 |
| HSA-MIR-4261 | 99.59 | 70.30 | 3415 |
| HSA-MIR-6758-3P | 99.57 | 67.55 | 1078 |
| HSA-MIR-513C-5P | 99.50 | 68.42 | 1730 |
| HSA-MIR-514B-5P | 99.50 | 68.19 | 1766 |
| HSA-MIR-5009-3P | 99.45 | 69.43 | 1341 |
| HSA-MIR-942-5P | 99.41 | 68.40 | 1977 |
| HSA-MIR-519D-5P | 99.41 | 69.30 | 2057 |
| HSA-MIR-3140-5P | 99.39 | 69.04 | 1136 |
| HSA-MIR-3191-5P | 99.24 | 66.52 | 1722 |
| HSA-MIR-4291 | 99.20 | 68.88 | 2969 |
| HSA-MIR-361-3P | 99.19 | 66.45 | 1381 |
Cross-species orthologs
8 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | arpc5lb | ENSDARG00000035433 |
| danio_rerio | arpc5la | ENSDARG00000041720 |
| mus_musculus | Arpc5l | ENSMUSG00000026755 |
| rattus_norvegicus | Arpc5l | ENSRNOG00000014317 |
| rattus_norvegicus | Arpc5l-ps1 | ENSRNOG00000067388 |
| drosophila_melanogaster | Arpc5 | FBGN0031437 |
| caenorhabditis_elegans | arx-7 | WBGENE00000205 |
| caenorhabditis_elegans | C46H11.3 | WBGENE00016729 |
Paralogs (1): ARPC5 (ENSG00000162704)
Protein
Protein identifiers
Actin-related protein 2/3 complex subunit 5-like protein — Q9BPX5 (reviewed: Q9BPX5)
Alternative names: Arp2/3 complex 16 kDa subunit 2
All UniProt accessions (2): A0A024R897, Q9BPX5
UniProt curated annotations — full annotation on UniProt →
Function. May function as component of the Arp2/3 complex which is involved in regulation of actin polymerization and together with an activating nucleation-promoting factor (NPF) mediates the formation of branched actin networks.
Subunit / interactions. May be a component of the Arp2/3 complex in which it may replace ARPC5.
Subcellular location. Cytoplasm. Cytoskeleton.
Similarity. Belongs to the ARPC5 family.
RefSeq proteins (1): NP_112240* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR006789 | ARPC5 | Family |
| IPR036743 | ARPC5_sf | Homologous_superfamily |
Pfam: PF04699
UniProt features (4 total): sequence conflict 2, chain 1, modified residue 1
Structure
Experimental structures (PDB)
3 structures.
| PDB | Method | Resolution (Å) |
|---|---|---|
| 9I2B | ELECTRON MICROSCOPY | 3 |
| 8P94 | ELECTRON MICROSCOPY | 3.3 |
| 6YW6 | ELECTRON MICROSCOPY | 4.2 |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q9BPX5-F1 | 89.33 | 0.65 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (1): 64
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 235 (showing top):
RNGTGGGC_UNKNOWN, GOBP_REGULATION_OF_PROTEIN_POLYMERIZATION, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, NAGASHIMA_NRG1_SIGNALING_UP, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOBP_REGULATION_OF_ACTIN_FILAMENT_BASED_PROCESS, WEI_MYCN_TARGETS_WITH_E_BOX, GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_SIZE, GOBP_ACTIN_FILAMENT_ORGANIZATION, GOBP_REGULATION_OF_PROTEIN_CONTAINING_COMPLEX_ASSEMBLY, TGANTCA_AP1_C, RYTTCCTG_ETS2_B, GOMF_ACTIN_BINDING, BASAKI_YBX1_TARGETS_UP, MARTINEZ_RESPONSE_TO_TRABECTEDIN_DN
GO Biological Process (3): cell migration (GO:0016477), regulation of actin filament polymerization (GO:0030833), Arp2/3 complex-mediated actin nucleation (GO:0034314)
GO Molecular Function (3): actin binding (GO:0003779), protein-macromolecule adaptor activity (GO:0030674), protein binding (GO:0005515)
GO Cellular Component (9): Arp2/3 protein complex (GO:0005885), focal adhesion (GO:0005925), cortical cytoskeleton (GO:0030863), extracellular exosome (GO:0070062), glutamatergic synapse (GO:0098978), cytoplasm (GO:0005737), cytoskeleton (GO:0005856), actin cytoskeleton (GO:0015629), synapse (GO:0045202)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cytoskeleton | 2 |
| cell motility | 1 |
| regulation of actin polymerization or depolymerization | 1 |
| actin filament polymerization | 1 |
| regulation of protein polymerization | 1 |
| actin nucleation | 1 |
| cytoskeletal protein binding | 1 |
| protein binding | 1 |
| molecular adaptor activity | 1 |
| binding | 1 |
| actin cytoskeleton | 1 |
| protein-containing complex | 1 |
| cell-substrate junction | 1 |
| cell cortex | 1 |
| extracellular vesicle | 1 |
| synapse | 1 |
| intracellular anatomical structure | 1 |
| cellular anatomical structure | 1 |
| intracellular membraneless organelle | 1 |
| cell junction | 1 |
Protein interactions and networks
STRING
1250 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| ARPC5L | ARPC1B | O15143 | 909 |
| ARPC5L | ARPC1A | Q92747 | 865 |
| ARPC5L | ARPC3 | O15145 | 816 |
| ARPC5L | ARPC2 | O15144 | 800 |
| ARPC5L | ACTR3B | Q9P1U1 | 732 |
| ARPC5L | ACTR3 | P32391 | 660 |
| ARPC5L | ACTR2 | P61160 | 647 |
| ARPC5L | ACTG1 | P02571 | 632 |
| ARPC5L | WASL | O00401 | 481 |
| ARPC5L | SNX27 | Q96L92 | 459 |
| ARPC5L | ACTR3C | Q9C0K3 | 453 |
| ARPC5L | SPCS2 | Q15005 | 447 |
| ARPC5L | SPCS3 | P12280 | 438 |
| ARPC5L | WAS | P42768 | 404 |
| ARPC5L | CFTR | P13569 | 375 |
IntAct
133 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| ARPC1B | ARPC2 | psi-mi:“MI:0915”(physical association) | 0.920 |
| ARPC1B | ARPC2 | psi-mi:“MI:0914”(association) | 0.920 |
| ARPC4 | ARPC1B | psi-mi:“MI:0914”(association) | 0.910 |
| ARPC1A | ARPC2 | psi-mi:“MI:0914”(association) | 0.900 |
| ARPC1A | ARPC2 | psi-mi:“MI:0915”(physical association) | 0.900 |
| ARPC5L | ARPC4 | psi-mi:“MI:0915”(physical association) | 0.890 |
| ARPC4 | ARPC5L | psi-mi:“MI:0915”(physical association) | 0.890 |
| ACTR3 | ARPC1B | psi-mi:“MI:0914”(association) | 0.890 |
| ARPC3 | ARPC1B | psi-mi:“MI:0914”(association) | 0.880 |
| ARPC5L | ARPC1B | psi-mi:“MI:0914”(association) | 0.830 |
| CFTR | ESYT2 | psi-mi:“MI:0914”(association) | 0.710 |
| GADD45G | ARPC5L | psi-mi:“MI:0915”(physical association) | 0.670 |
BioGRID (184): ARPC5L (Affinity Capture-RNA), ARPC5L (Affinity Capture-RNA), ARPC5L (Affinity Capture-MS), ARPC5L (Affinity Capture-MS), ACTR3 (Co-fractionation), ARPC1A (Co-fractionation), ARPC2 (Co-fractionation), ARPC4-TTLL3 (Co-fractionation), ARPC4 (Co-fractionation), ARPC5L (Co-fractionation), ARPC5L (Co-fractionation), ARPC5L (Co-fractionation), ARPC5L (Co-fractionation), CAPZB (Co-fractionation), ARPC5L (Affinity Capture-MS)
ESM2 similar proteins: A1C987, A1D9P1, A1L108, A3GGB4, A3LPQ8, A5DMM1, A5DPQ5, A6S043, B0YEH1, B3H6Y2, C4YCB9, G5EES6, O14164, O15511, O74432, O96626, P0CN46, P0CN47, P0CN54, P0CN55, P40518, P91167, Q09722, Q0CVT0, Q10316, Q1DP77, Q2H731, Q2U0Q9, Q3SYX9, Q4KLF8, Q4P0P0, Q4PHN4, Q4W9S8, Q4WDK4, Q5AX75, Q5E963, Q5R4M1, Q5R516, Q641B9, Q68FI4
Diamond homologs: A1L108, B3H6Y2, O15511, O96626, P91167, Q3SYX9, Q4KLF8, Q5E963, Q5R4M1, Q5R516, Q641B9, Q68FI4, Q6DE18, Q9BPX5, Q9CPW4, Q9D898, Q9M117, Q10316, P40518
SIGNOR signaling
0 interactions.
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 109 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| Parasite infection | 12 | 62.0× | 4e-17 |
| Leishmania phagocytosis | 12 | 62.0× | 4e-17 |
| Fcgamma receptor (FCGR) dependent phagocytosis | 12 | 49.9× | 6e-16 |
| RHO GTPases activate PAKs | 6 | 48.7× | 5e-08 |
| RHO GTPases Activate WASPs and WAVEs | 10 | 47.4× | 3e-13 |
| EPHB-mediated forward signaling | 10 | 39.6× | 2e-12 |
| Regulation of actin dynamics for phagocytic cup formation | 13 | 35.7× | 2e-15 |
| FCGR3A-mediated phagocytosis | 12 | 33.5× | 7e-14 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| Arp2/3 complex-mediated actin nucleation | 7 | 83.8× | 7e-10 |
| platelet aggregation | 5 | 19.1× | 8e-04 |
| neuron projection morphogenesis | 5 | 15.7× | 2e-03 |
| cellular response to type II interferon | 5 | 11.8× | 4e-03 |
| actin cytoskeleton organization | 9 | 8.1× | 4e-04 |
| actin filament organization | 6 | 8.1× | 6e-03 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
23 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 18 |
| Likely benign | 2 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
934 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 9:124863985:C:G | acceptor_gain | 1.0000 |
| 9:124863986:A:AG | acceptor_gain | 1.0000 |
| 9:124863987:G:GG | acceptor_gain | 1.0000 |
| 9:124863987:GCC:G | acceptor_gain | 1.0000 |
| 9:124863987:GCCA:G | acceptor_gain | 1.0000 |
| 9:124864104:CAAGG:C | donor_loss | 1.0000 |
| 9:124864105:AAG:A | donor_loss | 1.0000 |
| 9:124864106:AGGTG:A | donor_loss | 1.0000 |
| 9:124864109:T:A | donor_loss | 1.0000 |
| 9:124874970:TGCAG:T | acceptor_loss | 1.0000 |
| 9:124874971:GCA:G | acceptor_loss | 1.0000 |
| 9:124874972:CA:C | acceptor_loss | 1.0000 |
| 9:124874972:CAGG:C | acceptor_gain | 1.0000 |
| 9:124874973:A:AG | acceptor_gain | 1.0000 |
| 9:124874973:AG:A | acceptor_gain | 1.0000 |
| 9:124874973:AGG:A | acceptor_loss | 1.0000 |
| 9:124874973:AGGA:A | acceptor_gain | 1.0000 |
| 9:124874974:G:A | acceptor_loss | 1.0000 |
| 9:124874974:G:GG | acceptor_gain | 1.0000 |
| 9:124874974:GG:G | acceptor_gain | 1.0000 |
| 9:124874974:GGA:G | acceptor_gain | 1.0000 |
| 9:124874974:GGAG:G | acceptor_gain | 1.0000 |
| 9:124874974:GGAGC:G | acceptor_gain | 1.0000 |
| 9:124875079:G:GT | donor_gain | 1.0000 |
| 9:124862231:G:GT | donor_gain | 0.9900 |
| 9:124862234:G:GT | donor_gain | 0.9900 |
| 9:124862254:G:GG | donor_gain | 0.9900 |
| 9:124862399:G:GT | donor_gain | 0.9900 |
| 9:124863983:CACA:C | acceptor_loss | 0.9900 |
| 9:124863985:CA:C | acceptor_loss | 0.9900 |
AlphaMissense
994 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 9:124869318:T:C | F10L | 1.000 |
| 9:124869320:C:A | F10L | 1.000 |
| 9:124869320:C:G | F10L | 1.000 |
| 9:124875140:T:A | W130R | 1.000 |
| 9:124875140:T:C | W130R | 1.000 |
| 9:124869321:C:A | R11S | 0.999 |
| 9:124875075:T:C | L108S | 0.999 |
| 9:124875089:T:G | Y113D | 0.999 |
| 9:124875095:G:C | G115R | 0.999 |
| 9:124875135:T:C | L128P | 0.999 |
| 9:124875141:G:C | W130S | 0.999 |
| 9:124875142:G:C | W130C | 0.999 |
| 9:124875142:G:T | W130C | 0.999 |
| 9:124875143:C:G | H131D | 0.999 |
| 9:124876899:G:C | G141R | 0.999 |
| 9:124876900:G:A | G141D | 0.999 |
| 9:124876912:G:C | R145T | 0.999 |
| 9:124876912:G:T | R145I | 0.999 |
| 9:124876936:T:A | V153D | 0.999 |
| 9:124869319:T:C | F10S | 0.998 |
| 9:124873764:G:C | K74N | 0.998 |
| 9:124873764:G:T | K74N | 0.998 |
| 9:124875006:T:A | L85H | 0.998 |
| 9:124875006:T:C | L85P | 0.998 |
| 9:124875042:T:A | V97E | 0.998 |
| 9:124875087:T:A | I112N | 0.998 |
| 9:124875099:T:C | F116S | 0.998 |
| 9:124875132:T:C | L127S | 0.998 |
| 9:124875135:T:A | L128H | 0.998 |
| 9:124875144:A:C | H131P | 0.998 |
dbSNP variants (sampled 300 via entrez): RS1000070012 (9:124876698 C>T), RS1000199376 (9:124874615 G>A), RS1000368212 (9:124868841 C>T), RS1000408117 (9:124873867 G>C), RS1000527160 (9:124871304 G>A), RS1000693726 (9:124875464 A>G), RS1000820478 (9:124869933 G>A), RS1000933793 (9:124864470 T>A), RS1001238372 (9:124877709 A>AAAG), RS1001267089 (9:124868167 G>C), RS1001360537 (9:124873015 C>T), RS1001371271 (9:124862510 T>A), RS1001386188 (9:124864129 T>C), RS1001506741 (9:124862844 T>A), RS1001824326 (9:124869071 A>G)
Disease associations
OMIM: gene `` | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
0 associations (top):
Drugs & pharmacology
Drug and pharmacology data
Is drug target: yes
ChEMBL targets (1): CHEMBL6066486 (SINGLE PROTEIN)
PharmGKB: 1 entry (VIP=true, CPIC=false)
ChEMBL bioactivities
2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).
| pChembl | Type | Value | Unit | Molecule |
|---|---|---|---|---|
| 7.58 | Kd | 26.29 | nM | CHEMBL5653589 |
| 7.46 | ED50 | 34.7 | nM | CHEMBL5653589 |
PubChem BioAssay actives
1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.
| Compound | Assay | Type | Value | Unit |
|---|---|---|---|---|
| 4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide | 2147894: Binding affinity to human ARPC5L incubated for 45 mins by Kinobead based pull down assay | kd | 0.0263 | uM |
CTD chemical–gene interactions
45 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| bisphenol F | increases expression, affects cotreatment, decreases expression | 2 |
| bisphenol A | decreases expression, affects cotreatment | 2 |
| Tobacco Smoke Pollution | increases expression, affects expression | 2 |
| Particulate Matter | decreases expression | 2 |
| aristolochic acid I | increases expression | 1 |
| FR900359 | increases phosphorylation | 1 |
| dicrotophos | decreases expression | 1 |
| 2,4,6-tribromophenol | increases expression | 1 |
| alpha-pinene | affects cotreatment, decreases expression, increases abundance | 1 |
| decabromobiphenyl ether | increases expression | 1 |
| arsenite | increases reaction, affects binding | 1 |
| sodium arsenite | increases expression | 1 |
| butyraldehyde | increases expression | 1 |
| tetrabromobisphenol A | increases expression | 1 |
| potassium chromate(VI) | affects cotreatment, increases expression | 1 |
| methacrylaldehyde | affects cotreatment, decreases expression, increases abundance | 1 |
| epigallocatechin gallate | affects cotreatment, increases expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| 2-palmitoylglycerol | increases expression | 1 |
| hexabrominated diphenyl ether 153 | increases expression | 1 |
| 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine | decreases expression, increases response to substance | 1 |
| bisphenol S | affects expression | 1 |
| PCI 5002 | affects cotreatment, increases expression | 1 |
| bisphenol AF | increases expression | 1 |
| Acrolein | affects cotreatment, decreases expression, increases abundance | 1 |
| Air Pollutants | affects cotreatment, decreases expression, increases abundance | 1 |
| Arsenic | affects methylation | 1 |
| Dexamethasone | affects cotreatment, decreases expression | 1 |
| Diazinon | increases methylation | 1 |
| Diethylstilbestrol | decreases expression | 1 |
ChEMBL screening assays
1 unique, capped per target: 1 binding
Representative assays (with source publication via chembl_document):
| Assay ID | Type | Description | Source paper |
|---|---|---|---|
| CHEMBL5650936 | Binding | Binding affinity to human ARPC5L incubated for 45 mins by Kinobead based pull down assay | NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem |
Cellosaurus cell lines
1 cell lines: 1 transformed cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_B2S7 | Abcam HEK293T ARPC5L KO | Transformed cell line | Female |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.